Search Results - yang+feng

4 Results

Sort By:

Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors

Summary: The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use. Description of Technology: Chimeric antigen receptor (CAR)-T...

Published: 12/20/2024 | Inventor(s): Brad St. Croix, Pradip Bajgain, Yang Feng

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing

Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor...

Published: 5/22/2024 | Inventor(s): Brad St. Croix, Yang Feng, Steven Seaman

Keywords(s): ADC, antibody drug conjugate, B7-H3, CD276, Immunotherapy, Monoclonal Antibody, St. Croix

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)

Abstract: The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment. Therapeutics...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng

Keywords(s): ANTIBODY, death receptor, Dr4, Mab, TRAIL

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Therapeutic antibody-drug conjugates targeting CD56-positive cancers

Abstract: The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng, Zhongyu Zhu, John Maris, Robyn Sussman

Keywords(s): ADC, GLYCOPROTEIN, MULTIPLE MYELOMA, Neuroblastoma, pyrrolobenzodiazepine, small-cell lung cancer

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing